CareDx Pty Ltd

CareDx Pty Ltd specializes in in vitro diagnostic (IVD) devices primarily focused on transplant medicine. Their portfolio includes tests for hematopoietic cell transplantation (HCT) and solid organ transplants, such as the AlloSeq Tx series for donor-recipient tissue typing, AlloSeq HCT for genetic profiling, and AlloSeq cfDNA assays for analyzing cell-free DNA. They also offer software tools, like the AlloSeq cfDNA Software, to support digital health applications in transplant care.

CareDx Pty Ltd is based in Australia. While the company operates from Australia, its IVD devices must comply with regulatory requirements in markets where they are used, including the European Union. For example, their devices listed in the EU are classified under IVD Annex II List B and the general IVD category, and they are registered in the EU’s eudamed database to meet EU regulatory standards.

CareDx’s IVD devices are listed in the EU’s eudamed registry, which is the official database for medical devices authorized in the European Economic Area. Listing in eudamed ensures transparency and compliance with EU regulations, allowing healthcare providers, regulators, and patients to verify the legitimacy and classification of the devices under the applicable IVD categories (Annex II List B and general IVD).

CareDx’s IVD devices are classified under two EU regulatory frameworks: IVD Annex II List B and the general IVD category. This classification determines the level of scrutiny and regulatory requirements they must meet before being authorized for use in the EU. For instance, Annex II List B devices undergo additional risk assessments due to their higher potential impact on patient health, while general IVD devices follow standard regulatory pathways. Both classifications ensure these diagnostics meet safety, performance, and quality standards before entering the market.